The Use of Methotrexate in Dermatology / Upotreba metotreksata u dermatologiji

1. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007;20(4): 216-28.10.1111/j.1529-8019.2007.00135.x17970887Search in Google Scholar

2. Milojević M. Citotoksična sredstva. U: Karadaglić Đ.Dermatologija. Beograd: Vojnoizdavački zavod; 2000. str. 2251-6.Search in Google Scholar

3. Barker J, Horn EJ, Lebwohl M, Warren RB,Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011;25(7):758-64.10.1111/j.1468-3083.2010.03932.x21198946Search in Google Scholar

4. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological diseasemodifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68(7):1105-12.10.1136/ard.2008.099861268952619054823Search in Google Scholar

5. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology 2007;46(10):1520-4.10.1093/rheumatology/kem14717586865Search in Google Scholar

6. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67(1):44-9.10.1111/j.1365-2125.2008.03303.x266808319076159Search in Google Scholar

7. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009;48(5):569-72.10.1093/rheumatology/kep02319273538Search in Google Scholar

8. Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006;24(5):805-11.10.1111/j.1365-2036.2006.03047.x16918884Search in Google Scholar

9. Carneiro SC, Cassia FF, Lamy F, Chagas VL, Ramos-e-Silva M. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J Eur Acad Dermatol Venereol 2008;22(1):25-9.Search in Google Scholar

10. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol 2005;6(6):357-63.Search in Google Scholar

11. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009;160(3):622-8.10.1111/j.1365-2133.2008.08876.x18945303Search in Google Scholar

12. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2006;55(2):366-7.10.1016/j.jaad.2006.01.07216844540Search in Google Scholar

13. Kozub P, Simaljakova M. Systemic therapy of psoriasis: methotrexate. Bratisl Lek Listy 2011;112(7):390-4.Search in Google Scholar

14. Morgan SL, Baggott JE. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010;28(61):102-9.Search in Google Scholar

15. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000;14(5):382-8.10.1046/j.1468-3083.2000.00058.x11305380Search in Google Scholar

16. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60(5):824-37.10.1016/j.jaad.2008.11.90619389524Search in Google Scholar

17. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.10.1016/j.jaad.2009.03.02719493586Search in Google Scholar

18. Chladek J, Simkova M, Vaneckova J, Hroch M, ChladkovaJ, Martinkova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008;64(4):347-55.10.1007/s00228-007-0442-x18163165Search in Google Scholar

19. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006;54(6):1013-8.10.1016/j.jaad.2006.01.00416713455Search in Google Scholar

20. Jager ME, Jong EM, Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010;62(6):1013-30.10.1016/j.jaad.2009.06.04819900732Search in Google Scholar

21. Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009;34(3):295-8.10.1111/j.1365-2230.2008.02907.x19175782Search in Google Scholar

22. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J Cutan Med Surg 2001;5(4):299-302.10.1177/120347540100500403Search in Google Scholar

23. Patton T, Korman N. Role of methotrexate in the treatment of bullous pemphigoid in the elderly. Drugs Aging 2008;25(8):623-9.10.2165/00002512-200825080-0000118665656Search in Google Scholar

24. Mutasim DF. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging 2010;27(1):1-19.10.2165/11318600-000000000-0000020030429Search in Google Scholar

25. Marie I. Therapy of polymyositis and dermatomyositis. Presse Med 2011;40(4):257-70.10.1016/j.lpm.2010.12.01221334847Search in Google Scholar

26. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10(6):365-81.10.2165/11310780-000000000-0000019824738Search in Google Scholar

27. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010;11(3):157-70.10.2165/11530070-000000000-0000020184391Search in Google Scholar

28. Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008;68(10):1361-83.10.2165/00003495-200868100-0000318578557Search in Google Scholar

29. Krunić A. Keratoakantom. U: Karadaglić Đ. Dermatologija. Beograd: Vojnoizdavački zavod; 2000. str. 834-41.Search in Google Scholar

30. Graham RM. Reiter’s disease. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL, editors. Textbook ofdermatology. 5th ed. Oxford: Blackwell Scientific Publications; 1992. p. 2455-67.Search in Google Scholar

31. Mestel DS, Beyer M, Steinhoff M, Sterry W,Assaf C.The treatment of mycosis fungoides. Ital Dermatol Venereol 2008;143(6):395-408.Search in Google Scholar

32. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007;33(2):146-60.10.1016/j.ctrv.2006.08.00617275192Search in Google Scholar

33. Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3(3):148-55.10.1038/ncprheum043617334337Search in Google Scholar

34. Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J 2008;10(6):413-4.Search in Google Scholar

35. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-tosevere adult atopic eczema. Br J Dermatol 2007;156(2):346-51.10.1111/j.1365-2133.2006.07686.x17223876Search in Google Scholar

36. Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol 2010;27(5):476-80.10.1111/j.1525-1470.2010.01258.x20796242Search in Google Scholar

37. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 2009;160(5):1075-82.10.1111/j.1365-2133.2008.09017.x19210503Search in Google Scholar

38. Jang N, Fischer G. Treatment of erosive vulvovaginal lichen planus with methotrexate. Australas J Dermatol 2008;49(4):216-9.10.1111/j.1440-0960.2008.00472.x18855784Search in Google Scholar

39. Sharma VK, Bhat R, Sethuraman G, Manchanda Y. Treatment of parthenium dermatitis with methotrexate. Contact Dermatitis 2007;57(2):118-9.10.1111/j.1600-0536.2006.00950.x17627653Search in Google Scholar

40. Kacar N, Tasli L, Argenziano G, Demirkan N. Reticulohistiocytosis: different dermatoscopic faces and a good response to methotrexate treatment. Clin Exp Dermatol 2010;35(4):120-2.10.1111/j.1365-2230.2009.03738.x19886958Search in Google Scholar

41. Lazaridou E, Fotiadou C, Tsorova C, Trachana M, Trigoni A, Patsatsi A, et al. Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate. Int J Dermatol 2010;49(2):215-7.10.1111/j.1365-4632.2009.04325.x20465649Search in Google Scholar